Schizophrenia today: Do we know any more and can we treat it better than a decade ago?

Current Opinion in Psychiatry

Volumn 21, Issue 2, 2008, Pages 131-132

  DeLisi, Lynn E ^a,c   Fleischhacker, W Wolfgang ^b  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^c NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

DRUG EFFICACY; DRUG MECHANISM; EDITORIAL; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENETIC VARIABILITY; HUMAN; IMAGING AND DISPLAY; MEDICAL RESEARCH; MENTAL DISEASE; NEUROIMAGING; SCHIZOPHRENIA;

BRAIN; HUMANS; MAGNETIC RESONANCE IMAGING; SCHIZOPHRENIA;

EID: 40349091132     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/YCO.0b013e3282f5f294     Document Type: Editorial

References (1)

1. Patil ST, Zhang L, Martenyi F, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat Med 2007; 13:1102-1107.